Physician profile
Ilyas Ikramuddin
NPI 1457352940
$3,627.26
in general payments reported to CMS, 2019-2025
27 companies · $44.15 in 2025
The $44.15 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $552 · 2020: $196 · 2021: $32.74 · 2022: $64.01 · 2023: $1,274 · 2024: $1,464 · 2025: $44.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,782.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $881.82 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $468.68 | 2023-2024 | Zeposia |
| Celgene Corporation | $379.55 | 2023-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $309.91 | 2019-2024 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $244.37 | 2019-2024 | Stelara, Remicade, Simponi Aria |
| Genzyme Corporation | $199.68 | 2022-2025 | |
| Madrigal Pharmaceuticals | $165.91 | 2024 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $152.22 | 2023 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $138.29 | 2019-2024 | Entyvio, Gattex |
| Phathom Pharmaceuticals, INC. | $136.49 | 2024 | Voquezna |
| Qol Medical, LLC | $88.58 | 2023-2024 | Sucraid, Sucraid |
| Pfizer INC. | $79.05 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $52.33 | 2023 | Dupixent |
| Ironwood Pharmaceuticals, INC | $48.44 | 2019-2023 | Linzess |
| Braintree Laboratories, INC. | $40.37 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $36.70 | 2019-2020 | |
| Organon LLC | $35.96 | 2024 | |
| Merck Sharp & Dohme LLC | $24.21 | 2019 | |
| Romark Laboratories, Lc | $22.36 | 2020 | |
| Allergan, INC. | $20.57 | 2019 | |
| Pharmacosmos Therapeutics INC. | $19.04 | 2024 | Monoferric |
| Ucb, INC. | $17.18 | 2019 | |
| Shionogi INC | $15.54 | 2019 | |
| Evoke Pharma, INC. | $15.04 | 2024 | |
| Nestle Healthcare Nutrition INC. | $14.30 | 2023 | |
| Daiichi Sankyo INC. | $10.78 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $9.89 | 2024 | Biopsy Forceps |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ilyas Ikramuddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.